News
ANIK
14.80
-1.20%
-0.18
Anika Therapeutics grants 3,138 RSUs to new hire under inducement plan
Reuters · 5h ago
Weekly Report: what happened at ANIK last week (0323-0327)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 03/23 12:05
Weekly Report: what happened at ANIK last week (0316-0320)?
Weekly Report · 03/23 09:46
Weekly Report: what happened at ANIK last week (0309-0313)?
Weekly Report · 03/16 09:46
Weekly Report: what happened at ANIK last week (0302-0306)?
Weekly Report · 03/09 09:47
Anika Therapeutics Earnings Call Signals Cautious Rebound
TipRanks · 03/08 00:25
Top 2 Health Care Stocks That May Crash This Quarter
Benzinga · 03/04 13:55
Based on the provided HTML file, it appears to be a financial report in the format of an annual 10-K filing with the US Securities and Exchange Commission (SEC). The title of the article is likely to be the company's name, which is not explicitly stated in the provided text. However, based on the company's ticker symbol "ANI" and the mention of "Clear Street LLC" and "May 2024 Share Repurchase Plan", it is likely that the company is Anika Therapeutics, Inc.
Therefore, the title of the article could be "Anika Therapeutics, Inc. 2025 Annual Report (10-K)" or "Anika Therapeutics, Inc. 2025 Annual Report".
Press release · 03/03 11:21
Weekly Report: what happened at ANIK last week (0223-0227)?
Weekly Report · 03/02 09:47
Anika Therapeutics Q4 Profit Challenges Narratives Around Ongoing Losses For ANIK Investors
Simply Wall St · 02/27 23:33
Anika Therapeutics Is Maintained at Outperform by Barrington Research
Dow Jones · 02/27 21:12
Anika Therapeutics Price Target Raised to $17.00/Share From $16.00 by Barrington Research
Dow Jones · 02/27 21:12
Anika Therapeutics (ANIK) Receives a Buy from B. Riley Securities
TipRanks · 02/27 14:26
Anika Therapeutics price target raised to $17 from $16 at Barrington
TipRanks · 02/27 14:22
Anika Therapeutics price target raised to $18 from $16 at B. Riley
TipRanks · 02/27 14:17
Anika signals 1%–9% revenue growth outlook for 2026 while expanding commercial channel and streamlining operations
Seeking Alpha · 02/26 18:58
Anika Announces Executive Transition Amid Stable Quarterly Results
TipRanks · 02/26 12:58
Anika Therapeutics reports Q4 EPS 31c vs (3c) last year
TipRanks · 02/26 12:27
Anika Therapeutics sees FY26 revenue $114M-$122.5M
TipRanks · 02/26 12:26
More
Webull provides a variety of real-time ANIK stock news. You can receive the latest news about Anika Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANIK
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.